Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: FDA FY 1999 goals

This article was originally published in The Tan Sheet

Executive Summary

FDA FY 1999 goals: Public reports from the Special Nutritionals Adverse Events Monitoring System will at least double in 1999 from the current two per year, FDA says in its FY 1999 budget justification. The agency notes it will "continue to respond to safety concerns associated with the rapidly expanding use and misuse of dietary supplement products such as ephedra." Regarding OTCs, FDA expresses its commitment to improving "the legibility and clarity of OTC drug labels" and "the consumer's ability to read and understand important warnings and usage directions." The President's budget request for FDA was issued Feb. 2 ("The Tan Sheet" Feb. 9, p. 15)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel